Dow Biomedical, a specialized company in vitro diagnostic medical devices, celebrated its 20th anniversary by unveiling its mid-to-long-term development plans at Dow Cafe Campus. The development plans, conceptualized as designing the next 20 years based on assets accumulated over the past two decades, mark a significant quantitative and qualitative transformation in achieving exponential growth and establishing corporate culture.

During the special inaugural ceremony, an awards ceremony was held to honor employees who have contributed over the years. The newly introduced slogan "Do it Art," symbolizing Dow's corporate culture, encourages working like artists and creating artworks. It embodies the core spirit of creativity, a key competency of Dow as market developers.

At the Do it Art awards ceremony, held on this occasion, 15 achievement awards, a 20th Anniversary Commemorative Plaque, and letters of appreciation were presented, creating an atmosphere more akin to an awards ceremony than a mere inaugural event.

Among these, the 20th Anniversary Commemorative Plaque, named after the newly revised corporate culture Dow Code, was awarded to employees who embody the meaning of this corporate culture with names like Do it Art Award, Campus Award, Lighthouse Keeper Award, Art Seeker Award, Pipe Award, and Seed Award. This underscored the establishment of corporate culture.

The most positively received award during the ceremony was the Long Service Award. Employees who have served for 10 years received a significant gold key equivalent to 10 mon, while those with 5 years received a gold key worth 5 mon, boosting employee morale.

Representative Shin Young-gil remarked, "Dow's 20th anniversary is thanks to the dedication of all our employees. With gratitude, we have established a corporate culture named Dow Code, aiming to become a better workplace for our employees. Although we established Dow Code, it will become our guiding star in shaping our future and sow the seeds of a corporate culture that brings qualitative change to Dow."

As part of its mid-to-long-term growth strategy for the next 20 years, Dow has set out to △ secure technology leadership in the market (techno hegemony) △ pioneer new diagnostic testing fields. Techno hegemony includes products in the liquid biopsy field such as new technologies expected to be released in 2024, including ctDNA, cfDNA, CTC, ddPCR, and MassARRY. Having led the diagnostic industry for the past seven years with NGS (Next Generation Sequencing), Dow aims to usher in the NGS 2.0 era, a growth phase where the testing method is extensively used.

Founded in 2004, Dow Biomedical specializes in in vitro diagnostic medical device platforms and has been supplying state-of-the-art in vitro diagnostic medical devices to the medical field for over 20 years. In 2024, in addition to its existing diagnostic product line, Dow announced its vision to expand its business areas by adding health screening products such as GastroPanel for precise stomach diagnostics and Freelite for multiple myeloma diagnostics. This expansion aims to contribute to national health across broader domains as Dow prepares for the era of great challenges.